====== High-Grade Glioma Diagnosis ======

see [[Glioma Diagnosis]].

see [[Glioblastoma diagnosis]].
----
Results highlighted the role of [[PTX3]] and [[TIMP1]] which were previously considered in [[Gliomagenesis]] as well as [[LTF]] as a new potential [[biomarker]]
((Ahmadi-Beni R, Shahbazi S, Khoshnevisan A. An integrative bioinformatics investigation and experimental validation of critically involved genes in high-grade gliomas. Diagn Pathol. 2022 Sep 24;17(1):73. doi: 10.1186/s13000-022-01253-0. PMID: 36153549.)).
----
[[Neurite orientation dispersion]] (NODDI) seems to be useful in reflecting the [[high-grade glioma]] infiltration to [[corticospinal tract]] (CST), and can evaluate the CST destruction with a performance similar to [[DTI]] by providing additional information about neurite density for HGG-induced CST injury
((Jiang R, Hu X, Deng K, Jiang S, Chen W, Zhang Z. Neurite orientation dispersion and density imaging in evaluation of high-grade glioma-induced corticospinal tract injury. Eur J Radiol. 2021 May 2;140:109750. doi: 10.1016/j.ejrad.2021.109750. Epub ahead of print. PMID: 33991969.)).
----
Fujioka et al. established a novel, non-invasive [[molecular diagnostics]] using a chip-based [[digital PCR]] system targeting [[circulating tumor DNA]] derived from [[CSF]] with high [[sensitivity]] and [[specificity]], especially for [[high-grade glioma]]s
((Fujioka Y, Hata N, Akagi Y, Kuga D, Hatae R, Sangatsuda Y, Michiwaki Y, Amemiya T, Takigawa K, Funakoshi Y, Sako A, Iwaki T, Iihara K, Mizoguchi M. Molecular diagnosis of diffuse glioma using a chip-based digital PCR system to analyze IDH, TERT, and H3 mutations in the cerebrospinal fluid. J Neurooncol. 2021 Jan 8. doi: 10.1007/s11060-020-03682-7. Epub ahead of print. PMID: 33417137.)).
----
Usually, [[low-grade glioma]]s show no increase in tumor rCBV, whereas high-grade gliomas demonstrate high [[relative cerebral blood volume]] (rCBV) that in some cases even extends outside the contrast-enhancing portions of the tumor
((Hu L. S. et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 33, 69–76, 10.3174/ajnr.A2743 (2012).)). 

see [[Stereotactic biopsy of high-grade glioma ]].

They require [[MGMT]], [[isocitrate dehydrogenase]] ([[IDH]]) and [[1p/19q co-deletion]] status, the determination
of these [[molecular]] diagnostics should be prioritized

===== High-Grade Glioma Magnetic resonance imaging =====

[[High-Grade Glioma Magnetic resonance imaging]].